MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients - Annals of Oncology
MET genetic lesions in non-small-cell lung cancer: pharmacological and clinical implications - Zorzetto - Translational Lung Cancer Research
EMT, MET amplification, and IGF-1R confer resistance to EGFR TKIs.... | Download Scientific Diagram
Clinical analysis by next-generation sequencing for NSCLC patients with MET amplification resistant to osimertinib - Lung Cancer
MET amplification and epithelial-to-mesenchymal transition exist as parallel resistance mechanisms in erlotinib-resistant, EGFR -mutated, NSCLC HCC827 cells | Oncogenesis
MET Inhibition in Non-Small Cell Lung Cancer - European Medical Journal
Targeting the MET Pathway for Lung Cancer Treatments, Biomarkers
Targeting MET in Lung Cancer: Will Expectations Finally Be MET? - Journal of Thoracic Oncology
new-molecular-drivers-in-nsclc-the-role-of-met
The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping - Cancer Treatment Reviews
MET Signaling: Novel Targeted Inhibition and Its Clinical Development in Lung Cancer - Journal of Thoracic Oncology
DISSECT platform with multi-omics data and various analytic tools - CNGBdb
The race to target MET exon 14 skipping alterations in non-small cell lung cancer: The Why, the How, the Who, the Unknown, and the Inevitable - ScienceDirect
Reciprocal and Complementary Role of MET Amplification and EGFR T790M Mutation in Acquired Resistance to Kinase Inhibitors in Lung Cancer | Clinical Cancer Research
Early Alectinib Resistance From MET Amplification in ALK Rearranged NSCLC: Response to Crizotinib with Re-response to Alectinib and Crizotinib - Clinical Lung Cancer
Chidamide increases the sensitivity of non-small cell lung cancer to crizotinib by decreasing c-MET mRNA methylation | bioRxiv
Novel Therapies for Metastatic Non-Small Cell Lung Cancer with MET Exo | LCTT
Treatment of Non–Small-Cell Lung Cancer with Erlotinib or Gefitinib
MET amplification results in heterogeneous responses to osimertinib in EGFR-mutant lung cancer treated with erlotinib.,Cancer Science - X-MOL
MET/HGF pathway activation as a paradigm of resistance to targeted therapies - Ko - Annals of Translational Medicine
Capmatinib in MET Exon 14–Mutated or MET-Amplified Non–Small-Cell Lung Cancer | NEJM
Tracking MET de-addiction in lung cancer: A road towards the oncogenic target - ScienceDirect
Reciprocal relationship between MET amplification and T790M mutation.... | Download Scientific Diagram
